Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alignment Healthcare, Inc.ALHC · Entity 4269 | Director | March 13, 2026 | March 17, 2026 |
| Cigna GroupCI · Entity 550 | Director | April 22, 2026 | April 24, 2026 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | Director | April 23, 2026 | April 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alignment Healthcare, Inc.
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 370,531 |
Reported balance
After 2026-03-13 transaction · row 1
1 source rowRow 1 · 2026-03-13 · Grant · Acquired 13,096 · Balance 370,531 F1: Represents 13,096 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 13,096 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date.
Cigna Group
Report date April 22, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 6,891 |
Reported balance
After 2026-04-22 transaction · row 1
1 source rowRow 1 · 2026-04-22 · Grant · Acquired 782 · Balance 6,891 |
JOHNSON & JOHNSON
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 21,278.593 |
Reported balance
After 2026-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 975 · Balance 21,278.593 F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).
F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cigna Holding Co
Report date December 20, 2018 · Filed December 26, 2018
Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 201 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)
F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2026 Filed Apr 27, 2026 22:06 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000102 · wk-form4_1777327601.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,278.593 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:58 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001739940-26-000036 · wk-form4_1777064329.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,891 Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:57 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | GrantCommon Stock | 13,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-018853 · wk-form4_1773781029.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,531 F1 · shares: Represents 13,096 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. Read SEC document |
| April 24, 2025 Filed Apr 28, 2025 21:50 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,316 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000131 · wk-form4_1745877052.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,755.232 Underlying: Common Stock · 1,316 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 20:32 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004425 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,109 Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 22:25 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | GrantCommon Stock | 12,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-013266 · wk-form4_1742250295.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,435 F1 · shares: Represents 12,258 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 21:06 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,385.697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005331 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,867.715 Underlying: Common Stock · 1,385.697 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 21:14 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 539 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005290 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,471 Read SEC document |
| March 13, 2024 Filed Mar 16, 2024 00:00 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004878 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,177 F1 · kind: Represents 30,000 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. Read SEC document |
| April 27, 2023 Filed May 2, 2023 21:21 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,193.975 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005254 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,996.899 Underlying: Common Stock · 1,193.975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 21:10 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 765 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005158 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,932 Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:00 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | GrantCommon Stock | 21,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017843 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,177 F1 · kind: Represents 21,802 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:11 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 757 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006305 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:11 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | GrantCommon Stock | 16,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017994 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,375 F1 · kind: Represents 16,556 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock of the Company, all of which will vest on the one-year anniversary of the grant date unless the reporting person ceases to serve as a member of the Board of Directors prior to such date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:07 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 199 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003937 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,410 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:46 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002581 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,322.637 Underlying: Common Stock · 1,175 shares Expires not disclosed F1 · security: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 23:35 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 247 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-014398 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,211 Read SEC document |
| November 23, 2021 Filed Nov 24, 2021 23:34 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | SaleCommon Stock | 7,500 | $20.11 | $150,806.25 |
DisclosureSEC source: 0000950142-21-003817 · es210205309_4-mcclellan.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,819 F1 · kind: Represents 7,500 shares of Common Stock sold pursuant to a registered offering which closed on November 23, 2021, at a price of $20.1075 (net of underwriting discount). Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:55 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 224 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-011983 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,964 Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 21:12 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008831 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,740 Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 00:30 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | SaleCommon Stock | 12,103 | $16.83 | $203,693.49 |
DisclosureSEC source: 0000899243-21-015437 · doc4.xml · nonDerivative · entry 2 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,319 F2 · kind: Represents 12,103 shares of Common Stock sold pursuant to the partial exercise by the underwriters of their over-allotment option after the closing of the Company's initial public offering, at a price of $16.83 (net of underwriting discount). Read SEC document |
| March 25, 2021 Filed Apr 9, 2021 00:30 UTC | Alignment Healthcare, Inc. ALHC · Entity 4269 | GrantCommon Stock, par value $0.001 per share ("Common Stock") | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-015437 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,422 F1 · kind: Represents 33,333 shares of restricted Common Stock that will vest in equal annual installments on each of the first three anniversaries of the initial public offering of Alignment Healthcare, Inc. (the "Company") unless Mr. McClellan is removed for cause or resigns prior to such dates. The securities covered by such transaction were previously included on Mr. McClellan's Form 3. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:29 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 226 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004294 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,557 Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 22:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002223 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,818.379 Underlying: Common Stock · 1,123 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:33 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 227 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-014154 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,331 Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 21:36 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 267 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-011222 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,104 Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:14 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-008488 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,837 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:06 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 259 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004184 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:09 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002159 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,380.897 Underlying: Common Stock · 1,221 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 00:41 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015092 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,338 Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:34 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012168 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101 Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 21:14 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008812 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:38 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 272 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004406 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473 Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 19:55 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002423 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,884.291 Underlying: Common Stock · 1,402 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 18:47 UTC | Cigna Holding Co CI · Entity 161580 | Disposition to issuerCommon Stock, $.25 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008663 · doc1.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 00:19 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008709 · doc1.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 18:28 UTC | Cigna Holding Co CI · Entity 161580 | GrantCommon Stock, $.25 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016218 · doc4.xml · nonDerivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003070 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,262.236 Underlying: Common Stock · 1,428 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 02:59 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003484 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,665.707 Underlying: Common Stock · 1,512 shares Expires not disclosed F1 · security: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_price: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 08, 2016 Filed Feb 10, 2016 23:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-026039 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,012.744 Underlying: Common Stock · 1,629 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 09, 2015 Filed Feb 12, 2015 01:16 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-003641 · doc4.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,283.81 Underlying: Common Stock · 1,524 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon the Reporting Person's retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 10, 2014 Filed Feb 12, 2014 23:28 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantDeferred Share Units · Derivative | 1,713 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-14-000024 · edgar.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,713 Underlying: Common Stock · 1,713 shares Expires not disclosed F1 · security: Grant of Deferred Share Units issued to Non-Employee Directors under the Issuer's Amended and Restated Deferred Fee Plan for Directors. Deferred Share Units are to be settled in cash upon the Reporting Person's Retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_price: Grant of Deferred Share Units issued to Non-Employee Directors under the Issuer's Amended and Restated Deferred Fee Plan for Directors. Deferred Share Units are to be settled in cash upon the Reporting Person's Retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units issued to Non-Employee Directors under the Issuer's Amended and Restated Deferred Fee Plan for Directors. Deferred Share Units are to be settled in cash upon the Reporting Person's Retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units issued to Non-Employee Directors under the Issuer's Amended and Restated Deferred Fee Plan for Directors. Deferred Share Units are to be settled in cash upon the Reporting Person's Retirement (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.